Recently, we welcomed a new customer from the Netherlands who inquired about the Retatrutide peptide product. After a brief understanding of the product specifications, quality inspection standards, and packaging methods, they quickly confirmed their order intention and completed the purchase formally. The process from the initial inquiry to the final order placement was very smooth, demonstrating the customer's trust in professional services and our ability to respond quickly to international demands. After entering the order processing stage, we strictly followed the warehouse assembly process to ensure that the product labels were clear and met the requirements for long-distance transportation. We promptly provided freight tracking information. After the goods were dispatched, the logistics status was continuously traceable. Recently, feedback from the customer confirmed that this batch of goods has been safely delivered to the designated address in the Netherlands, with the appearance intact. The customer expressed their approval of the delivery timeliness and packaging integrity. This initial cooperation communication had low costs and high execution efficiency, laying a good foundation for future long-term exchanges. We will continue to maintain the standardized service process and win the trust of more overseas customers with reliable delivery quality.
business process
Retatrutide is a peptide-based drug that has gained attention in the field of metabolic disease treatment. Its unique mechanism of action lies in simultaneously targeting three naturally occurring hormone receptors - the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. These three receptors play crucial roles in human energy metabolism, blood sugar regulation, and appetite control. By simultaneously activating these three targets, Retatrutide can exert synergistic effects at multiple levels: GIP and GLP-1 help improve insulin secretion and delay gastric emptying, while the activation of the glucagon receptor is believed to increase energy expenditure, inhibit appetite, and promote fat metabolism. This triple synergistic mechanism design has demonstrated unique research value in the management of type 2 diabetes and obesity.
Application in the management of type 2 diabetes
Type 2 diabetes is a common chronic metabolic disorder worldwide, characterized by imbalanced glucose regulation and insulin resistance. It is notable that approximately 90% of patients with type 2 diabetes also suffer from overweight or obesity. For this group, merely controlling blood sugar without achieving meaningful weight management still poses risks of complications such as hypertension, abnormal lipid levels, and cardiovascular diseases caused by obesity. One of the primary goals of Retatrutide's design is to address both the need for glucose control and weight management simultaneously.
TRANSCEND-T2D-1 is a 3-phase clinical trial for Retatrutide, involving adult patients with type 2 diabetes who have a relatively short disease duration (averaging approximately 2.5 years), have failed to achieve satisfactory blood sugar control through diet and exercise.
The study included 537 participants and randomly assigned them to different doses of Retatrutide or the placebo group. The treatment period was 40 weeks.
The results showed that all dose groups of Retatrutide achieved statistically significant reductions in glycated hemoglobin (HbA1c): the 12-mg dose group reduced by approximately 1.94% from baseline, while the placebo group reduced by approximately 0.81%.
At the same time, the Retatrutide group also performed well in weight management, with an average weight loss of approximately 15.3% (about 16.8 kilograms) in the 12-mg dose group, compared to a 2.6% reduction in the placebo group.
The study also observed that among the participants who reached the composite endpoint of HbA1c ≤ 6.5% and weight loss ≥ 10%, more than half of the Retatrutide group achieved this goal, indicating that the drug has potential in simultaneously improving blood sugar and weight.
Additionally, Retatrutide showed improvements in cardiovascular metabolic indicators such as lipid profile and blood pressure.
Application in the Management of Obesity and Related Complications
Obesity itself is a complex chronic disease that is closely associated with various complications, including obstructive sleep apnea, knee osteoarthritis, and non-alcoholic fatty liver disease, among others. The exploration of Retatrutide in the field of obesity is also based on its metabolic regulatory effects brought about by its triple receptor agonist mechanism.
The TRIUMPH series of clinical trials are important research projects of Retatrutide in the field of obesity and its complications. Among them, the TRIUMPH-1 study included over 2,300 obese or overweight participants, and the design specifically included subgroups with combined knee osteoarthritis and obstructive sleep apnea.
Data released from the American Diabetes Association Scientific Congress showed that in the 80-week treatment period, the subjects in the highest-dose group (12 mg, once a week) achieved an average weight reduction of 28.3%. This data reflects the research prospects of Retatrutide in weight management, and the study is also paying attention to its effects on obstructive sleep apnea and pain symptoms of knee osteoarthritis.
Exploratory study on metabolic-related complications
Apart from blood sugar and weight management, the potential applications of Retatrutide in metabolic-related complications have also attracted attention. Non-alcoholic fatty liver disease is a liver metabolic disorder closely related to obesity and type 2 diabetes, and currently, the available treatment options are relatively limited.
Retatrutide, due to its agonistic effect on glucagon receptors, theoretically may exert certain effects by promoting liver fat metabolism. Relevant clinical studies are currently underway.Furthermore, an animal study published in the journal "Behavioral Brain Research" explored the impact of Retatrutide on cognitive functions related to diabetes.
The study used a streptozotocin-induced diabetic rat model and found that Retatrutide treatment not only lowered blood sugar levels but also alleviated the neuroinflammatory response in the hippocampus (as indicated by a decrease in TNF-α levels), and improved the spatial learning and memory abilities of diabetic rats in the water maze behavioral test.
The researchers believed that this effect may result from the combined action of blood sugar control and neuroprotective mechanisms. It should be noted that these findings are currently limited to animal models, and their effects on human cognitive functions need further verification.
Summary and Outlook
Overall, Retatrutide, as a triple agonist that simultaneously targets the GIP, GLP-1, and glucagon receptors, is designed to exert its effects synergistically through multiple metabolic pathways.
Data from existing Phase 3 clinical trials indicate that this peptide has demonstrated relatively positive effects in both glycemic control and weight management in patients with type 2 diabetes; in the field of obesity, the weight loss observed during long-term treatment has also drawn attention.
Meanwhile, studies are underway to evaluate its potential in treating complications such as obstructive sleep apnea, knee osteoarthritis, and non-alcoholic fatty liver disease; these investigations will contribute to a more comprehensive assessment of the drug's clinical value.
Of course, the clinical application of any new drug must undergo a rigorous regulatory approval process, and its long-term efficacy and safety require further confirmation through larger-scale, longer-term studies.